Medtech grants in Ireland

Scheduled

Funds €7–10M programmes that bring better cancer diagnosis and treatment trials to patients across four or more European countries.

Scheduled

Funds three €5–7M projects that make cancer control more equitable, effective and cost-aware for patients and families.

Scheduled

Funds two €12M projects using living labs to remediate carcinogenic soils and trace cancer risks through people, food, water and air.

Scheduled

Funds €8–10M procurer consortia to bring affordable cancer technologies, devices and medicines from tender to patient benefit.

Scheduled

Funds one €3M coordination action that helps cancer charities and funders improve quality of life for young survivors across Europe.

Scheduled

Funds €7–10M projects that advance living-cell bio-printing from laboratory proof toward regenerative medicine.

Scheduled

Funds €10–12M projects that make Virtual Human Twins useful for prevention, diagnosis and safer clinical decisions.

Scheduled

Funds a European community and roadmap for trustworthy frontier AI models in healthcare.

Between cycles

Funds late stage deep tech start ups and small businesses with combined non dilutive and growth support across technology fields.

Between cycles

Invests in scale-up ventures in digital, clean technology, and biotechnology through equity to accelerate commercialization pathways.

Between cycles

Funds researchers 5 to 15 years past their PhD who are building an independent research team in Europe through an ERC Consolidator Grant.

Between cycles

Funds innovative SME-led international R&D consortia through the Eurostars Call 12 grant process.

Between cycles

Supports ARPA inspired high risk demand driven pilots translating new approach methods into practical deep tech practice.

Between cycles

Funds bottom-up research for breakthrough deep-tech, any field of science.

Between cycles

Supports EIC beneficiaries' participation in major trade fairs across the EU, MENA and the US.

Between cycles

Funds early-stage deep tech startups developing solutions at TRL 4-5 in collaboration with industry partners through a 4-month co-creation programme.

Between cycles

Runs research teams and institutions for EIT Health Catapult Edition in biotechnology, medical technology, and artificial intelligence.

Between cycles

Supports international consortia so small companies can turn joint innovation into export-ready products.

Between cycles

Offers market-feasibility support for small companies exploring non-European markets through Europe-wide innovation networks.

Between cycles

Offers European health founders early support from EIT Health through mentorship, networks, and commercialization guidance.

Funds clinical trials of prophylactic vaccines against neglected tropical diseases such as schistosomiasis, leishmaniasis and leprosy in sub-Saharan Africa.

Closed

Funds early clinical trials of therapies built from the molecules cells secrete rather than the cells themselves, aiming for an off-the-shelf alternative to cell therapy.

Funds a flagship project that federates EU health data and pilots AI tools for cardiovascular risk prediction, prevention and personalised care.

Funds AI teams building generative-AI tools for clinical-dataset enhancement or automotive crash-test case generation, paying up to €100,000 in prizes after an initial €28,500 concept-stage award.